XCancer

Imaging Tumor Hypoxia With 18F-EF5 PET in Recurrent or Metastatic Clear Cell Ovarian Cancer

Description:

The purpose of this study is to use 18F-EF5 PET/CT scans to locate areas with low oxygen levels (hypoxia) in patients with recurrent and/or metastatic cancer.

Sponsor:

British Columbia Cancer Agency

Contacts:

Anna Tinker, MD, FRCPC (PRINCIPAL_INVESTIGATOR)

Government Study Link:

NCT01881451 - Click here to see study on

ClinicalTrials.gov

EF5

Isotope(s):
Target(s):
  • Hypoxia
Ligand Class: Small Molecules
Inclusion
  • Must be able to provide written informed consent, and willing to comply with protocol procedures of the study
  • * Histologically confirmed, advanced metastatic or recurrent clear cell cancer of the ovary
  • Off all active therapy for at least 4 weeks (cytotoxic chemotherapy, radiation, immune therapy, hormone therapy, clinical trials or new agents)
  • At least one index lesion measuring 2 cm in diameter
Exclusion
  • Previous history of cancer, except treated non-melanoma skin cancer, non-invasive breast cancer, non-invasive cervical cancer; or curatively treated solid cancer with no evidence of recurrence for more than 5 years.
  • * Renal failure (eGFR \< 50mls/min)
  • Receiving or had received active therapy in the form or chemotherapy or radiation within 4 weeks of the PET scan
  • Patients with unknown primaries
  • ECOG status ≥ 3